\
&
Contact us
Published on | 11 months ago
ProgrammesOn 16 July, the Commission put forward its proposal for the next European Programme for Research & Innovation for the period 2028-2034. The Commission proposes a continuation of Horizon Europe after 2027 with an enhanced budget of €175 billion and a new four-pillar structure:
The Commission also envisages to streamline the programme implementation, including reducing the number of topics and shortening the time from call closure to grant signature.
With a proposed €175 billion budget and tightly connected to the upcoming European Competitiveness Fund, the next framework programme proposed by the Commission aims to boost Europe’s productivity and competitiveness, while also improving the well-being of EU citizens. The proposal and accompanying proposed budget are not final as they will have to go through a long period of interinstitutional negotiations between the European Parliament, the member states and the Commission, with an agreement envisioned by the end of 2027.
Find out more in the Commission’s press release. More background information on the publication of the Commission proposal is available in a recent article on Science Business. More information on the Commission proposal for the next overarching Multiannual Financial Framework for 2028 - 2034 here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.